• ryanjamesjessup

BioMolecular Imaging | Business Development

Updated: Apr 28

BioMolecular Imaging can serve in an advisory role for venture investments in imaging companies and for merger and acquisition activities.

Providing investment advice and strategic support for start-ups or for mature companies, including those focused on development of new diagnostics, imaging hardware, or image analytics.

The Owner of BioMolecular Imaging, Dr. J. James Frost, is currently an investor in early stage companies, has served as a board member, and has advised VC companies in imaging company deals for over 20 years.

With this extensive experience integrated into the company’s core corporate values, we can easily represent both the investing or acquiring entity as well as imaging companies themselves.

The market economics and commercialization of new diagnostics, including adoption in clinical practice, is also an area where BioMolecular Imaging can assist your company.

About BioMolecular Imaging

BioMolecular Imaging (BMI Consultants) is a molecular imaging and clinical trial consultancy owned and operated by Dr. J. James Frost M.D./Ph.D out of Baltimore Maryland. BMI has been involved with clinical, therapeutic & diagnostic imaging focused on Oncology, Brain, Biomarkers, Cardiology and Central Image Interpretations for over 20 years.

To learn more about BioMolecular Imaging, please visit or connect with:

SoundCloud -

Facebook -

Twitter -

LinkedIn -

YouTube -

Copyright © 2022 BioMolecular Imaging

BioMolecular Imaging is a registered trademark of BioMolecular Imaging D.B.A. BMI Consultants

29 views0 comments

Recent Posts

See All

Diagnostic imaging is a core competency of BioMolecular Imaging - and is the approach of imaging the human body to analyze and form medical intervention, especially when viewing the function of organs

Imaging in therapeutic trials is the key process in expanding the understanding, methodology and metrics which are required to make determinations in drug targeting and efficacy. This spans most all i

A very active area of current investigation and commercialization is molecular and functional biomarker development. These biomarkers can serve as surrogate endpoints for therapeutic efficacy and are